{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:06:48Z","timestamp":1793725608979,"version":"4.6.1"},"reference-count":184,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":2961,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1194\/jlr.r024190","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T09:54:45Z","timestamp":1338890085000},"page":"1767-1782","source":"Crossref","is-referenced-by-count":153,"title":["Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2"],"prefix":"10.1016","volume":"53","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Stafforini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.R024190_bib1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00041433-199810000-00008","article-title":"Oxidized phospholipids and isoprostanes in atherosclerosis","volume":"9","author":"Witztum","year":"1998","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R024190_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(08)60763-1","article-title":"Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Tardif","year":"2008","journal-title":"Lancet."},{"key":"10.1194\/jlr.R024190_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCIMAGING.110.937169","article-title":"Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome","volume":"3","author":"Tardif","year":"2010","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"10.1194\/jlr.R024190_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(09)60403-7","article-title":"Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial","volume":"373","author":"Rosenson","year":"2009","journal-title":"Lancet."},{"key":"10.1194\/jlr.R024190_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0b013e32833eb581","article-title":"Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes","volume":"21","author":"Rosenson","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R024190_bib7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1582-4934.2010.01022.x","article-title":"Epigenetics in atherosclerosis and inflammation","volume":"14","author":"Wierda","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1194\/jlr.R024190_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10557-008-6148-1","article-title":"Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease","volume":"23","author":"Rosenson","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1194\/jlr.R024190_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/HCO.0b013e32833aaa94","article-title":"Why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes","volume":"25","author":"White","year":"2010","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1194\/jlr.R024190_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0025-6196(11)60992-0","article-title":"Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review","volume":"82","author":"Garza","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"10.1194\/jlr.R024190_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cvr\/26.1.25","article-title":"Plasma platelet activating factor degradation and serum lipids after coronary bypass surgery","volume":"26","author":"Stephens","year":"1992","journal-title":"Cardiovasc. Res."},{"key":"10.1194\/jlr.R024190_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0049-3848(87)90141-1","article-title":"Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor","volume":"47","author":"Ostermann","year":"1987","journal-title":"Thromb. Res."},{"key":"10.1194\/jlr.R024190_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10557-008-6132-9","article-title":"Phospholipase A2 biochemistry","volume":"23","author":"Burke","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1194\/jlr.R024190_bib17","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.bbalip.2006.07.011","article-title":"The phospholipase A2 superfamily and its group numbering system","volume":"1761","author":"Schaloske","year":"2006","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R024190_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0090-1229(80)90044-6","article-title":"Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF)","volume":"15","author":"Farr","year":"1980","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1194\/jlr.R024190_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.biochem.69.1.419","article-title":"Platelet-activating factor and related lipid mediators","volume":"69","author":"Prescott","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"10.1194\/jlr.R024190_bib20","doi-asserted-by":"crossref","first-page":"17381","DOI":"10.1016\/S0021-9258(18)38167-5","article-title":"Platelet-activating factor","volume":"265","author":"Prescott","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib21","doi-asserted-by":"crossref","first-page":"9682","DOI":"10.1016\/S0021-9258(19)38724-1","article-title":"Human macrophages secret platelet-activating factor acetylhydrolase","volume":"265","author":"Stafforini","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib22","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1016\/S0021-9258(18)61335-3","article-title":"Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor","volume":"262","author":"Stafforini","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib23","doi-asserted-by":"crossref","first-page":"31151","DOI":"10.1074\/jbc.270.52.31151","article-title":"Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein","volume":"270","author":"Blencowe","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib24","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.270.43.25481","article-title":"Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad","volume":"270","author":"Tjoelker","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib25","doi-asserted-by":"crossref","first-page":"31617","DOI":"10.1074\/jbc.M804750200","article-title":"Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis","volume":"283","author":"Samanta","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10557-008-6133-8","article-title":"Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)","volume":"23","author":"Stafforini","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1194\/jlr.R024190_bib27","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1194\/jlr.R800024-JLR200","article-title":"The emerging roles of PAF acetylhydrolase","volume":"50","author":"McIntyre","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib28","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1016\/S0021-9258(18)99132-5","article-title":"Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates","volume":"266","author":"Stremler","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0022-2275(20)38359-0","article-title":"Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase","volume":"30","author":"Steinbrecher","year":"1989","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib30","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0891-5849(00)00234-3","article-title":"Bioactive phospholipid oxidation products","volume":"28","author":"Marathe","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1194\/jlr.R024190_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1074\/jbc.M608135200","article-title":"Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides","volume":"282","author":"Kriska","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib32","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1074\/jbc.M507340200","article-title":"Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases","volume":"281","author":"Stafforini","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib33","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1074\/jbc.M709970200","article-title":"Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein","volume":"283","author":"Davis","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib34","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1021\/bi101916w","article-title":"Lipoprotein-associated phospholipase A2 interacts with phospholipid vesicles via a surface-disposed hydrophobic alpha-helix","volume":"50","author":"Cao","year":"2011","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R024190_bib35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2362.1997.1570706.x","article-title":"Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia","volume":"27","author":"Karabina","year":"1997","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1194\/jlr.R024190_bib38","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ndt\/gfk043","article-title":"PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin","volume":"21","author":"Papavasiliou","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R024190_bib39","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1074\/jbc.274.11.7018","article-title":"Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein","volume":"274","author":"Stafforini","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib40","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1074\/jbc.M802394200","article-title":"Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein","volume":"283","author":"Gardner","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1567-5688(02)00045-4","article-title":"Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase","volume":"3","author":"Tselepis","year":"2002","journal-title":"Atheroscler. Suppl."},{"key":"10.1194\/jlr.R024190_bib42","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1038\/sj.ijo.0802498","article-title":"Macrophages, inflammation, and atherosclerosis","volume":"27","author":"Linton","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1194\/jlr.R024190_bib43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/374549a0","article-title":"Anti-inflammatory properties of a platelet-activating factor acetylhydrolase","volume":"374","author":"Tjoelker","year":"1995","journal-title":"Nature."},{"key":"10.1194\/jlr.R024190_bib44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jacc.2011.11.019","article-title":"Translational studies of lipoprotein-associated phospholipase A2 in inflammation and atherosclerosis","volume":"59","author":"Ferguson","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R024190_bib45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/STROKEAHA.107.503193","article-title":"Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques","volume":"39","author":"Mannheim","year":"2008","journal-title":"Stroke."},{"key":"10.1194\/jlr.R024190_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2009060615","article-title":"Distinct macrophage phenotypes contribute to kidney injury and repair","volume":"22","author":"Lee","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R024190_bib47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1160\/TH11-05-0320","article-title":"Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation","volume":"106","author":"Wolfs","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1194\/jlr.R024190_bib48","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1074\/jbc.273.7.4012","article-title":"Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation","volume":"273","author":"Cao","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4049\/jimmunol.170.1.167","article-title":"Differential expression of platelet-activating factor acetylhydrolase in macrophages and monocyte-derived dendritic cells","volume":"170","author":"Al-Darmaki","year":"2003","journal-title":"J. Immunol."},{"key":"10.1194\/jlr.R024190_bib50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/CIRCRESAHA.109.215715","article-title":"Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2","volume":"107","author":"Kadl","year":"2010","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.R024190_bib51","doi-asserted-by":"crossref","first-page":"36158","DOI":"10.1074\/jbc.M402454200","article-title":"The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib52","doi-asserted-by":"crossref","DOI":"10.1161\/circ.116.suppl_16.II_108","article-title":"Selective inhibition of lipoprotein-associated phospholipase A2 attenuates markers of plaque vulnerability in humans","volume":"116","author":"Shi","year":"2007","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI115020","article-title":"Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2","volume":"87","author":"Satoh","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R024190_bib54","doi-asserted-by":"crossref","unstructured":"Zheng, G. H., Xiong, S. Q., Mei, L. J., Chen, H. Y., Wang, T., Chu, J. F., . Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study. Inflammation. Epub ahead of print. March 20, 2012; doi:10.1007\/s10753-012-9455-4.","DOI":"10.1007\/s10753-012-9455-4"},{"key":"10.1194\/jlr.R024190_bib55","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1161\/ATVBAHA.109.196592","article-title":"Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs","volume":"29","author":"De Keyzer","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/eurheartj\/ehr372","article-title":"Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies","volume":"33","author":"Grallert","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R024190_bib57","doi-asserted-by":"crossref","first-page":"e1000928","DOI":"10.1371\/journal.pgen.1000928","article-title":"Genome-wide association study of Lp-PLA2 activity and mass in the Framingham Heart Study","volume":"6","author":"Suchindran","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1194\/jlr.R024190_bib58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cll.2006.06.003","article-title":"Lipoprotein-associated phospholipase A2","volume":"26","author":"McConnell","year":"2006","journal-title":"Clin. Lab. Med."},{"key":"10.1194\/jlr.R024190_bib59","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.RES.0000147310.18962.06","article-title":"Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac","volume":"95","author":"Birukov","year":"2004","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.R024190_bib65","doi-asserted-by":"crossref","unstructured":"McIntyre, T. M., . Bioactive oxidatively truncated phospholipids in inflammation and apoptosis: Formation, targets, and inactivation. Biochim. Biophys. Acta., Epub ahead of print. March 16, 2012; doi:10.1016\/j.bbamem.2012.03.004.","DOI":"10.1016\/j.bbamem.2012.03.004"},{"key":"10.1194\/jlr.R024190_bib66","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2010.03.011","article-title":"Phospholipase A2s: developing drug targets for atherosclerosis","volume":"212","author":"Suckling","year":"2010","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib69","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","volume":"50","author":"Berliner","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0021-9150(98)00297-4","article-title":"Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells","volume":"143","author":"Ozaki","year":"1999","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib73","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.2174\/092986707782793899","article-title":"Role of lysophosphatidylcholine (LPC) in atherosclerosis","volume":"14","author":"Matsumoto","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1194\/jlr.R024190_bib74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1194\/jlr.C400018-JLR200","article-title":"Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis","volume":"46","author":"Chen","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib75","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bj3380479","article-title":"Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor","volume":"338","author":"MacPhee","year":"1999","journal-title":"Biochem. J."},{"key":"10.1194\/jlr.R024190_bib80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/tx100323m","article-title":"Structure-activity analysis of diffusible lipid electrophiles associated with phospholipid peroxidation: 4-hydroxynonenal and 4-oxononenal analogues","volume":"24","author":"McGrath","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1194\/jlr.R024190_bib81","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2008.03.087","article-title":"Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages","volume":"370","author":"Olofsson","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1194\/jlr.R024190_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1042\/bj3450061","article-title":"Characterization of plasma unsaturated lysophosphatidylcholines in human and rat","volume":"345","author":"Croset","year":"2000","journal-title":"Biochem. J."},{"key":"10.1194\/jlr.R024190_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1476-511X-6-17","article-title":"Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status","volume":"6","author":"Taylor","year":"2007","journal-title":"Lipids Health Dis."},{"key":"10.1194\/jlr.R024190_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1476-9255-5-17","article-title":"Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines\u2019 unexpected therapeutic properties","volume":"5","author":"Cunningham","year":"2008","journal-title":"J. Inflamm. (Lond.)."},{"key":"10.1194\/jlr.R024190_bib85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOL.0b013e32832fa14d","article-title":"Lipoprotein modification by secretory phospholipase A2 enzymes contributes to the initiation and progression of atherosclerosis","volume":"20","author":"O\u00f6rni","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R024190_bib86","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1158\/1078-0432.CCR-04-1357","article-title":"Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin","volume":"10","author":"Edwards","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1194\/jlr.R024190_bib87","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1388-1981(00)00064-0","article-title":"The capacity of various non-esterified fatty acids to suppress lipid transfer inhibitor protein activity is related to their perturbation of the lipoprotein surface","volume":"1486","author":"Morton","year":"2000","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R024190_bib88","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/01.ATV.19.6.1437","article-title":"All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase","volume":"19","author":"Lee","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib89","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbalip.2009.10.011","article-title":"Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes","volume":"1801","author":"Yang","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R024190_bib90","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1161\/01.CIR.0000065220.70220.F7","article-title":"Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription","volume":"107","author":"Chen","year":"2003","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib91","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.immuni.2004.09.003","article-title":"Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization","volume":"21","author":"Angeli","year":"2004","journal-title":"Immunity."},{"key":"10.1194\/jlr.R024190_bib92","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","article-title":"Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group","volume":"343","author":"Packard","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R024190_bib93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7156\/v4i4p201","article-title":"Systematic review of the association between lipoprotein-associated phospholipase A2 and atherosclerosis","volume":"4","author":"Liu","year":"2011","journal-title":"N. Am. J. Med. Sci."},{"key":"10.1194\/jlr.R024190_bib94","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet."},{"key":"10.1194\/jlr.R024190_bib95","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1161\/CIRCULATIONAHA.110.936393","article-title":"Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers","volume":"122","author":"Mallat","year":"2010","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib96","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1373\/clinchem.2012.183475","article-title":"Lipoprotein-associated phospholipase A2 measurements: mass, activity, but little productivity","volume":"58","author":"Stein","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R024190_bib98","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1373\/clinchem.2011.180281","article-title":"Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial","volume":"58","author":"Ridker","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R024190_bib99","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1161\/01.CIR.0000143377.53389.C8","article-title":"Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany","volume":"110","author":"Koenig","year":"2004","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib102","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib103","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0735-1097(01)01554-6","article-title":"A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women","volume":"38","author":"Blake","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R024190_bib106","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2009.943","article-title":"Novel and conventional biomarkers for prediction of incident cardiovascular events in the community","volume":"302","author":"Melander","year":"2009","journal-title":"JAMA."},{"key":"10.1194\/jlr.R024190_bib107","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R024190_bib108","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ahj.2010.11.007","article-title":"Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women","volume":"161","author":"Hatoum","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1194\/jlr.R024190_bib109","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.0000222983.73369.c8","article-title":"Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress","volume":"26","author":"Koenig","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib111","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1161\/ATVBAHA.107.151670","article-title":"Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease","volume":"27","author":"Sabatine","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib112","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ahj.2006.01.011","article-title":"Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death","volume":"152","author":"May","year":"2006","journal-title":"Am. Heart J."},{"key":"10.1194\/jlr.R024190_bib113","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1373\/clinchem.2007.086298","volume":"53","author":"Winkler","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R024190_bib114","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00392-007-0540-x","article-title":"Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II)","volume":"96","author":"M\u00f6ckel","year":"2007","journal-title":"Clin. Res. Cardiol."},{"key":"10.1194\/jlr.R024190_bib115","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.ATV.0000240406.89440.0c","article-title":"Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community","volume":"26","author":"Gerber","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib116","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/eurheartj\/ehl565","article-title":"Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients","volume":"28","author":"Oldgren","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R024190_bib117","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.105.612630","volume":"113","author":"O'Donoghue","year":"2006","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib118","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/CIRCULATIONAHA.111.063487","article-title":"Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes","volume":"125","author":"Ryu","year":"2012","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib119","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2796.2010.02258.x","article-title":"Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality","volume":"268","author":"Heart Protection Study Collaborative Group","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1194\/jlr.R024190_bib120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2796.2010.02272.x","article-title":"Physicochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease","volume":"268","author":"Rosenson","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1194\/jlr.R024190_bib121","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1161\/01.ATV.19.12.2909","article-title":"Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions","volume":"19","author":"H\u00e4kkinen","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib122","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","article-title":"Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis","volume":"26","author":"Kolodgie","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R024190_bib123","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejvs.2011.10.009","article-title":"Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque","volume":"43","author":"Sarlon-Bartoli","year":"2012","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1194\/jlr.R024190_bib124","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000172633","article-title":"Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke","volume":"27","author":"Elkind","year":"2009","journal-title":"Cerebrovasc. Dis."},{"key":"10.1194\/jlr.R024190_bib125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.atherosclerosis.2011.09.019","article-title":"Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome","volume":"219","author":"Dohi","year":"2011","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib126","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/gme.0b013e3182163fea","article-title":"Gene expression signatures differ with extent of atherosclerosis in monkey iliac artery","volume":"18","author":"Eyster","year":"2011","journal-title":"Menopause."},{"key":"10.1194\/jlr.R024190_bib127","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0891-5849(02)00905-X","article-title":"Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression","volume":"33","author":"Zelko","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1194\/jlr.R024190_bib128","first-page":"381","article-title":"Atherosclerosis and oxidative stress","volume":"23","author":"Bonomini","year":"2008","journal-title":"Histol. Histopathol."},{"key":"10.1194\/jlr.R024190_bib129","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60488-6","article-title":"Lp-PLA2 and risk of atherosclerotic vascular disease","volume":"375","author":"Rosenson","year":"2010","journal-title":"Lancet."},{"key":"10.1194\/jlr.R024190_bib130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0025-6196(11)60990-7","article-title":"Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: not ready for \u201cprime time\u201d","volume":"82","author":"Steinberg","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"10.1194\/jlr.R024190_bib131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jama.2009.949","article-title":"Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment","volume":"302","author":"Shah","year":"2009","journal-title":"JAMA."},{"key":"10.1194\/jlr.R024190_bib132","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1172\/JCI118733","article-title":"Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase","volume":"97","author":"Stafforini","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R024190_bib133","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1172\/JCI113818","article-title":"Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children","volume":"82","author":"Miwa","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R024190_bib134","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9150(99)00385-8","article-title":"Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population","volume":"150","author":"Yamada","year":"2000","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1172\/JCI5574","article-title":"Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma","volume":"103","author":"Stafforini","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R024190_bib136","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1291\/hypres.30.403","article-title":"Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population","volume":"30","author":"Zhang","year":"2007","journal-title":"Hypertens. Res."},{"key":"10.1194\/jlr.R024190_bib137","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2006-0116","article-title":"The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men","volume":"91","author":"Jang","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1194\/jlr.R024190_bib138","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1538-7836.2006.01895.x","article-title":"Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction","volume":"4","author":"Liu","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1194\/jlr.R024190_bib139","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1007\/s11033-010-0529-9","article-title":"Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis","volume":"38","author":"Zheng","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1194\/jlr.R024190_bib140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00439-008-0587-4","article-title":"Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study","volume":"125","author":"Hou","year":"2009","journal-title":"Hum. Genet."},{"key":"10.1194\/jlr.R024190_bib141","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0049-3848(00)00394-7","article-title":"Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan","volume":"101","author":"Balta","year":"2001","journal-title":"Thromb. Res."},{"key":"10.1194\/jlr.R024190_bib142","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/ph2030094","article-title":"Functional consequences of mutations and polymorphisms in the coding region of the PAF acetylhydrolase (PAF-AH) gene","volume":"2","author":"Stafforini","year":"2009","journal-title":"Pharmaceuticals."},{"key":"10.1194\/jlr.R024190_bib143","doi-asserted-by":"crossref","unstructured":"Song, K., Nelson, M. R., Aponte, J., Manas, E. S., Bacanu, S. A., Yuan, X., Kong, X., Cardon, L., Mooser, V. E., Whittaker, J. C., . Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations. Pharmacogenomics J. Epub ahead of print. May 24, 2011; doi:10.1038\/tpj.2011.20.","DOI":"10.1038\/tpj.2011.20"},{"key":"10.1194\/jlr.R024190_bib146","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1194\/jlr.D300021-JLR200","article-title":"Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus","volume":"44","author":"Kujiraoka","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib147","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0026-0495(98)90216-5","article-title":"Identification of the G994\u2192T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men","volume":"47","author":"Yamada","year":"1998","journal-title":"Metabolism."},{"key":"10.1194\/jlr.R024190_bib150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1067\/mva.2000.105670","article-title":"Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan","volume":"32","author":"Unno","year":"2000","journal-title":"J. Vasc. Surg."},{"key":"10.1194\/jlr.R024190_bib151","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.atherosclerosis.2003.09.019","article-title":"Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia","volume":"172","author":"Shimokata","year":"2004","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib152","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ajh.2009.70","article-title":"Effects of G994T in the Lp-PLA2 gene on the plasma oxidized LDL level and carotid intima-media thickness in Japanese: the Shimane study","volume":"22","author":"Wang","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"10.1194\/jlr.R024190_bib153","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1469-1809.2011.00666.x","article-title":"Association between lipoprotein-associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population","volume":"75","author":"Li","year":"2011","journal-title":"Ann. Hum. Genet."},{"key":"10.1194\/jlr.R024190_bib154","doi-asserted-by":"crossref","first-page":"e18208","DOI":"10.1371\/journal.pone.0018208","article-title":"Carriage of the V279F null allele within the gene encoding Lp-PLA2 is protective from coronary artery disease in South Korean males","volume":"6","author":"Jang","year":"2011","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R024190_bib155","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cca.2009.12.021","article-title":"Effects of V279F in the Lp-PLA2 gene on markers of oxidative stress and inflammation in Koreans","volume":"411","author":"Paik","year":"2010","journal-title":"Clin. Chim. Acta."},{"key":"10.1194\/jlr.R024190_bib156","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1161\/CIRCULATIONAHA.109.923383","article-title":"PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry","volume":"121","author":"Casas","year":"2010","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib157","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1086\/302901","article-title":"The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma","volume":"66","author":"Kruse","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1194\/jlr.R024190_bib158","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(03)00086-8","article-title":"Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe","volume":"168","author":"Abuzeid","year":"2003","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib159","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.coph.2005.11.008","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target","volume":"6","author":"Macphee","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1194\/jlr.R024190_bib160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/156800605774962103","article-title":"Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis","volume":"5","author":"Zalewski","year":"2005","journal-title":"Curr. Drug Targets Cardiovasc. Haematol. Disord."},{"key":"10.1194\/jlr.R024190_bib161","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0960-894X(03)00058-1","article-title":"The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2","volume":"13","author":"Blackie","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1194\/jlr.R024190_bib162","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","article-title":"Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease","volume":"160","author":"White","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1194\/jlr.R024190_bib163","doi-asserted-by":"crossref","unstructured":"O'Donoghue, M. L., Braunwald, E., White, H. D., Serruys, P., Steg, P. G., Hochman, J., Maggioni, A. P., Bode, C., Weaver, D., Johnson, J. L., . 2011. Study design and rationale for the Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am. Heart J. 162: 613\u2013619.e1.","DOI":"10.1016\/j.ahj.2011.07.018"},{"key":"10.1194\/jlr.R024190_bib164","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1753944710375820","article-title":"Darapladib: an emerging therapy for atherosclerosis","volume":"4","author":"Corson","year":"2010","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1194\/jlr.R024190_bib165","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nm.1870","article-title":"Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development","volume":"14","author":"Wilensky","year":"2008","journal-title":"Nat. Med."},{"key":"10.1194\/jlr.R024190_bib166","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10557-008-6080-4","article-title":"Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-PLA2 reduces oxidized fatty acids","volume":"22","author":"Rosenson","year":"2008","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1194\/jlr.R024190_bib167","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/aps.2011.127","article-title":"The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice","volume":"32","author":"Hu","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1194\/jlr.R024190_bib168","doi-asserted-by":"crossref","first-page":"e23425","DOI":"10.1371\/journal.pone.0023425","article-title":"Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R024190_bib169","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0014-5793(01)02840-X","article-title":"Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages","volume":"505","author":"Carpenter","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1194\/jlr.R024190_bib171","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-2275(20)30154-1","article-title":"Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice","volume":"43","author":"Forte","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib172","doi-asserted-by":"crossref","first-page":"II365","DOI":"10.1161\/circ.100.suppl_2.Ii-365","article-title":"Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury","volume":"100","author":"Morgan","year":"1999","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib173","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2004.10.025","article-title":"Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta","volume":"179","author":"Turunen","year":"2005","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R024190_bib174","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1161\/01.CIR.103.20.2495","article-title":"Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice","volume":"103","author":"Quarck","year":"2001","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib175","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1096\/fj.99-1029com","article-title":"HDL-associated PAF-AH reduces endothelial adhesiveness in apoE\u2212\/\u2212 mice","volume":"14","author":"Theilmeier","year":"2000","journal-title":"FASEB J."},{"key":"10.1194\/jlr.R024190_bib176","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1161\/CIRCULATIONAHA.104.476242","volume":"111","author":"Arakawa","year":"2005","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib177","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1203\/PDR.0b013e3181eb2efe","article-title":"Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis","volume":"68","author":"Lu","year":"2010","journal-title":"Pediatr. Res."},{"key":"10.1194\/jlr.R024190_bib178","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"Mohler","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R024190_bib179","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.bbalip.2006.06.017","article-title":"Clinical aspects of plasma platelet-activating factor-acetylhydrolase","volume":"1761","author":"Karasawa","year":"2006","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R024190_bib180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R024190_bib181","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2362.2011.02634.x","article-title":"Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis","author":"Winkler","year":"2012","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1194\/jlr.R024190_bib182","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMp058139","article-title":"Nesiritide - not verified","volume":"353","author":"Topol","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R024190_bib183","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0090-6980(02)00015-1","article-title":"Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle","volume":"70","author":"Hase","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1194\/jlr.R024190_bib184","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clpt.2005.12.128","article-title":"A study to evaluate the effect of repeat oral doses of SB-480848 on platelet function as compared to placebo in healthy subjects","volume":"79","author":"Shaddinger","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1194\/jlr.R024190_bib12","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0022-2275(20)34942-7","article-title":"Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins","volume":"38","author":"Guerra","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/cs0820535","article-title":"Plasma platelet-activating factor degradation in patients with severe coronary artery disease","volume":"82","author":"Graham","year":"1992","journal-title":"Clin. Sci. (Lond.)."},{"key":"10.1194\/jlr.R024190_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0049-3848(88)90126-0","article-title":"The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients","volume":"52","author":"Ostermann","year":"1988","journal-title":"Thromb. Res."},{"key":"10.1194\/jlr.R024190_bib36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-2275(20)30167-X","article-title":"Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia","volume":"43","author":"Tsimihodimos","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R024190_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1253\/circj.71.214","article-title":"Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation","volume":"71","author":"Okamura","year":"2007","journal-title":"Circ. J."},{"key":"10.1194\/jlr.R024190_bib60","doi-asserted-by":"crossref","first-page":"24787","DOI":"10.1074\/jbc.274.35.24787","article-title":"Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein","volume":"274","author":"Watson","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature."},{"key":"10.1194\/jlr.R024190_bib62","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1074\/jbc.M107602200","article-title":"Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta","volume":"277","author":"Subbanagounder","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib63","doi-asserted-by":"crossref","first-page":"38503","DOI":"10.1074\/jbc.M203318200","article-title":"Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36","volume":"277","author":"Podrez","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib64","first-page":"31298","article-title":"Phospholipid hydroxyalkenals, a subset of recently discovered endogenous CD36 ligands, spontaneously generate novel furan-containing phospholipids lacking CD36 binding activity in vivo","volume":"281","author":"Gao","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib67","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.4049\/jimmunol.0903594","article-title":"Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation","volume":"185","author":"Oskolkova","year":"2010","journal-title":"J. Immunol."},{"key":"10.1194\/jlr.R024190_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nature01023","article-title":"Protective role of phospholipid oxidation products in endotoxin-induced tissue damage","volume":"419","author":"Bochkov","year":"2002","journal-title":"Nature."},{"key":"10.1194\/jlr.R024190_bib71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0014-5793(99)01049-2","article-title":"Lysophosphatidylcholine phosphorylates CREB and activates the jun2TRE site of c-jun promoter in vascular endothelial cells","volume":"457","author":"Ueno","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1194\/jlr.R024190_bib72","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.98.4.353","article-title":"Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration","volume":"98","author":"Kohno","year":"1998","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib76","doi-asserted-by":"crossref","first-page":"40676","DOI":"10.1074\/jbc.M507787200","article-title":"Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A","volume":"280","author":"Obinata","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R024190_bib77","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/db09-0848","article-title":"Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes","volume":"59","author":"Mas","year":"2010","journal-title":"Diabetes."},{"key":"10.1194\/jlr.R024190_bib78","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2353\/ajpath.2008.071150","article-title":"Inhibition of the lipopolysaccharide-induced stimulation of the members of the MAPK family in human monocytes\/macrophages by 4-hydroxynonenal, a product of oxidized omega-6 fatty acids","volume":"173","author":"Marantos","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1194\/jlr.R024190_bib79","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.102.033522","article-title":"4-hydroxynonenal decreases interleukin-6 expression and protein production in primary rat Kupffer cells by inhibiting nuclear factor-kappaB activation","volume":"302","author":"Luckey","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1194\/jlr.R024190_bib97","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1373\/clinchem.2008.103358","article-title":"Variability of lipoprotein-associated phospholipase A2 measurements","volume":"54","author":"McConnell","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R024190_bib100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.CIR.0000154553.12214.CD","article-title":"Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study","volume":"111","author":"Oei","year":"2005","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib101","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2007.10.048","article-title":"Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study","volume":"51","author":"Daniels","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R024190_bib104","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation."},{"key":"10.1194\/jlr.R024190_bib105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/eurheartj\/ehp010","article-title":"Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women","volume":"32","author":"Rana","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R024190_bib110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/eurheartj\/ehi010","article-title":"Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up","volume":"26","author":"Brilakis","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R024190_bib144","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1006\/bbrc.1997.7047","article-title":"Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281\u2192Arg mutation","volume":"236","author":"Yamada","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1194\/jlr.R024190_bib145","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10038-004-0151-6","article-title":"Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients","volume":"49","author":"Ishihara","year":"2004","journal-title":"J. Hum. Genet."},{"key":"10.1194\/jlr.R024190_bib148","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa021445","article-title":"Prediction of the risk of myocardial infarction from polymorphisms in candidate genes","volume":"347","author":"Yamada","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R024190_bib149","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/01.STR.28.12.2417","article-title":"A mutation in plasma platelet-activating factor acetylhydrolase (Val279\u2192Phe) is a genetic risk factor for stroke","volume":"28","author":"Hiramoto","year":"1997","journal-title":"Stroke."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752041822X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752041822X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.R024190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T22:48:27Z","timestamp":1637448507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002222752041822X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":184,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S002222752041822X"],"URL":"https:\/\/doi.org\/10.1194\/jlr.r024190","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}